J&J wins FDA approval for TRUFILL system to treat chronic subdural hematoma via middle meningeal artery embolization.

Johnson & Johnson MedTech announced that the FDA has approved an expanded indication for the company’s TruFill n-But ...

Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) have both announced recent regulatory milestones for liquid embolic ...

Background Middle meningeal artery (MMA) embolization results in fewer treatment failures than surgical evacuation for chronic subdural hematomas (cSDHs). We compared the total 1-year hospital cost ...

Chronic subdural hematoma (CSDH) is one of the most common neurosurgical conditions, particularly among the elderly, with an annual incidence ranging from 1.7 to 20.6 per 100,000 people. As the global ...

Chronic subdural hematoma (cSDH) is frequently encountered in neurosurgical practice. Apart from traditional treatment approaches, such as surgical intervention or medical management, middle meningeal ...

1. Across 18 U.S. centers, preference for surgical or conservative management for acute subdural hematoma (ASDH) varied widely but did not affect six-month functional outcomes. Evidence Rating Level: ...

Middle meningeal artery embolization with a liquid embolic is a minimally invasive adjunctive endovascular treatment for chronic subdural hematoma (cSDH). TRUFILL n‐butyl cyanoacrylate Liquid Embolic ...

‌A seroma is a buildup of clear fluid inside the body. It happens most often after surgery. A seroma is not often dangerous but can cause pain and discomfort. If you have a seroma, your doctor or care ...

A man in his late 30s was at a nightclub where he tripped, fell, and hit his head. The patient was stunned but was not knocked out, according to witnesses. Medics bring him to the emergency department ...

A peripheral IV was placed, and the patient was connected to a cardiac monitor, which showed atrial fibrillation and a heart rate of 70 beats/minute, which is a rare presentation but could be ...